Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1106 results about "Bronchitis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bronchitis is an inflammation of the bronchial tubes, the airways that carry air to your lungs. It causes a cough that often brings up mucus. It can also cause shortness of breath, wheezing, a low fever, and chest tightness. There are two main types of bronchitis: acute and chronic.
Compositions and methods for treating asthma and other lung disorders
InactiveUS20100008997A1Powder deliveryOrganic active ingredientsObstructive Pulmonary DiseasesOxygen
Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent.
Owner:REVALESIO CORP
Carbon monoxide as a biomarker and therapeutic agent
InactiveUS20020155166A1Reduce concentrationBiocideInorganic active ingredientsInterstitial lung diseaseRESPIRATORY DISTRESS SYNDROME ADULT
The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent of heart, lung, liver, spleen, brain, skin and kidney diseases and other conditions and disease states including, for example, asthma, emphysema, bronchitis, adult respiratory distress syndrome, sepsis, cystic fibrosis, pneumonia, interstitial lung diseases, idiopathic pulmonary diseases, other lung diseases including primary pulmonary hypertension, secondary pulmonary hypertension, cancers, including lung, larynx and throat cancer, arthritis, wound healing, Parkinson's disease, Alzheimer's disease, peripheral vascular disease and pulmonary vascular thrombotic diseases such as pulmonary embolism. CO may be used to provide anti-inflammatory relief in patients suffering from oxidative stress and other conditions especially including sepsis and septic shock. In addition, carbon monoxide may be used as a biomarker or therapeutic agent for reducing respiratory distress in lung transplant patients and to reduce or inhibit oxidative stress and inflammation in transplant patients.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Compositions and methods for treating asthma and other lung disorders
Provided are compositions and methods for treating or preventing lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis (e.g. nose respiratory tract), and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating a lung disorder or a symptom thereof is thereby afforded. Additional aspects relate to therapeutic compositions, and combination treatment methods comprising administration of at least one electrokinetically generated fluid in combination with at least one additional therapeutic agent.
Owner:REVALESIO CORP
Compositions and methods for treating asthma and other lung disorders
Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential and / or conductance, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination therapies comprising administration of the electrokinetically generated fluids with at least one additional therapeutic agent.
Owner:REVALESIO CORP
Therapeutic treatments using botulinum neurotoxin
ActiveUS20090232850A1Eliminates sensory inputImprove developmentBacterial antigen ingredientsNervous disorderDiseaseObstructive Pulmonary Diseases
Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and / or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and / or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis.
Owner:ALLERGAN INC
Soluble guanylate cyclase activators
The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble Guanylate Cyclase Activators
A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.
Owner:MERCK SHARP & DOHME LLC
Methods and compositions for disease treatment using inhalation
InactiveUS20120077786A1Increasing subject 's convenienceGood treatment complianceBiocideOrganic active ingredientsPulmonary edemaLung cancer
Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for treating complications associated with pulmonary disease such as corticosteroid resistance and pulmonary tissue destruction. The compositions of the present disclosure comprise corticosteroid resistance agents including but not limited to vitamin D, calcitriol and equivalents thereof. The compositions of the present disclosure also comprise alveolar development and maintenance agents including but not limited to vitamin A, ATRA and equivalents thereof. The present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.
Owner:MICRODOSE THERAPEUTX INC
Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
InactiveUS20050176761A1Useful in prevention of diseaseUseful in treatmentBiocideOrganic chemistryCystic fibrosisPneumatocele
Tetrhydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and / or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.
Owner:GENZYME CORP
Sulfonated derivative of andrographolide and combination of medication
ActiveCN1687049AClear structureGood antibacterialAntibacterial agentsPowder deliveryDiseaseTonsillitis
The present invention discloses II kinds of andrographolide sulfonated derivatives with the actions of resisting bacteria, relieving inflammation and reducing fever and medicine composition containing them. They can be used for preparing freeze-dried powder, injection or oral preparation, and can be used for curing the diseases of pneumonia, bronchitis, tonsillitis and bacillary dysentery, etc.
Owner:JIANGZI QINGFENG PHARMACEUTICALS INC
Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections
Medicinal use The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of respiratory syncitial virus (RSV) infection in particular viral exacerbation of a respiratory disorder such as bronchitis, asthma, COPD and / or cystic fibrosis, methods of treating or preventing RSV infection employing said compounds or pharmaceutical composition comprising the same.
Owner:RESPIVERT
Chicken infectivity bronchitis virus attenuated vaccine strain and application thereof
ActiveCN101514334AImprove securityNo side effectsInactivation/attenuationMicroorganism based processesInfectious bronchitisMicroorganism
The invention discloses a infectivity bronchitis attenuated vaccine strain LDT3-A strain, and discloses application and application effect thereof in preventing and curing chicken infectivity bronchitis. The microorganism accession number of the attenuated vaccine strain is CGMCC-2902. The attenuated vaccine strain of the present invention has good safety and good immunization protection effect to the chicken infectivity bronchitis. The attenuated strain can be prepared into single vaccine or combined vaccine for preventing or curing infectivity bronchitis virus.
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI +1
Formulations of DNase and Methods of Use Thereof
InactiveUS20080131497A1Efficient deliveryIncrease enzyme activityPeptide/protein ingredientsAerosol deliveryBronchitisLiposome
Compositions comprising DNase encapsulated in a liposome are provided. Additionally, provided are compositions comprising a free enzyme and empty liposomes, compositions comprising a free enzyme and an antiinfective encapsulated in a liposome, compositions comprising a free enzyme, a free-antiinfective, and empty liposomes, compositions comprising a free enzyme, a free antiinfective, and an antiinfective encapsulated in a liposome, and a composition comprising a free enzyme, empty liposomes, and an antiinfective encapsulated in a liposome, and compositions comprising a free enzyme, a free antiinfective, empty liposomes, an antiinfective encapsulated in a liposome, and pharmaceutical compositions comprising the aforementioned compositions. The Also provided are methods of treating pneumonia, bronchitis, cystic fibrosis, or emphysema comprising administering to a subject in need thereof a therapeutically effective amount of the aforementioned pharmaceutical composition.
Owner:TRANSAVE
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.
Owner:IMPETIS BIOSCI LTD
Method for treating pulmonary diseases using rho kinase inhibitor compounds
Owner:INSPIRE PHARMA
Medicine for treating bronchitis
InactiveCN101385848ASmall toxicityLow cost of treatmentRespiratory disorderPlant ingredientsVerbenaSide effect
The invention provides a medicine for treating bronchitis, which is prepared by taking the following traditional Chinese medicines as raw materials: boat-fruited stercrlia seed, bulbus fritillariae cirrhosae, tuber pinellia, dried orange peel, european verbena herb, shizandra berry, asarum, radix stemonae, white mulberry root-bark, folium eriobotryae, radix cynanchi, balloon flower, glossy privet fruit, common coltsfoot flower, liquorice, lily, fructus momordicae, heartleaf houttuynia herb, cassia twig, ophiopogon root, dried ginger, polygonatum and almond. The medicine is obtained after being tested by pharmacology and pharmacodynamics and has the efficacies on relieving cough and eliminating phlegm and preventing asthma. The prescription of the medicine in the invention is reasonable, the toxicity and side effect of the medicine is low, and the medicine for treating bronchitis has the advantages of low treatment expense, short course of treatment, rapid curative effect and high radical treatment rate. Besides, the extensive popularization of the machine can lead to good social benefit.
Owner:吴伶
Medicament containing gnetales for treating bronchitis and preparation method thereof
ActiveCN101549060APharmaceutical delivery mechanismPharmaceutical non-active ingredientsPinelliaForsythia
The invention provides a medicament containing gnetales for treating bronchitis and a preparation method thereof. The medicament contains gnetales, plaster, forsythia, scutellaria, cortex mori radicis, bitter almond, hogfennel root, tuber pinellia, and the like. The medicament composition combines various medicines to dissolve phlegm and relieve cough when phlegm heat in lung is removed, close canopy of lung qi is relieved, and the loss function is in a normal state. Research shows that the medicament has good effects for treating bronchitis in different aspects of relieving cough, removing phlegm and asthma and resisting inflammatory, and the like.
Owner:HEBEI YILING MEDICINE INST
Medicine for treating bronchitis and bronchial asthma suffered by children aging from three to seven
InactiveCN102526674AImprove immunityAchieve recoveryOrganic active ingredientsAnthropod material medical ingredientsDiseaseOfficinalis
The invention relates to a medicine for treating bronchitis and bronchial asthma suffered by children aging from three to seven, which is composed of Chinese medicine decoction and acupuncture point injection medicament. The active ingredients of the oral Chinese medicine decoction are composed of various Chinese herbal medicines of roast ephedra, schisandra chinensis, American ginseng, a gecko, zaocys dhumnade, morinda officinalis, lumbricus, semen ginkgo, semen brassicae, semen lepidii, radix pseudostellariae, ramulus cinnamomi, radix paeoniae alba, radix rehmanniae praeparata, fructus psoraleae, radix achyranthis bidentatae, lycium chinense, black ants, poria cocos, largehead atractylodes rhizome, Chinese yam, scorpio, saposhnidoviae radix, cortex magnoliae officinalis, ganoderma lucidum, blackberry lily, Semen cuscutae, cark plum fruit, roast cortex mori radicis, roast flos farfarae, roast radix stemonae, lily, fried almond, tendril-leaved fritillary bulb and the like. The acupuncture point injection medicament is one of nucleotide and casein, placenta tissue fluid or astragalus injection. The medicine can treat both principal and secondary aspects of diseases, perform dialectical therapy, increase immunity of the organism and enable the functions of the damaged lungs, spleens, kidneys and hearts to recover, and has the advantages and effects of high curative rate and no relapse.
Owner:孟庆云 +1
Canine combination vaccines
This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.
Owner:ZOETIS SERVICE LLC
Methods of treatment
The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or fragment thereof.
Owner:GLAXO SMITHKLINE LLC
Treatment of inflammation, respiratory tract infections and cystic fibrosis
InactiveUS20170239289A1Lower Level RequirementsAntibacterial agentsInorganic active ingredientsDiseaseVolumetric Mass Density
The present invention provides a method for treating a disease in a human subject in need thereof, wherein the disease is selected from the group consisting of inflammation, bronchiolitis and cystic fibrosis, and wherein the method comprises repeatedly administering to the human subject a gas mixture comprising nitric oxide at a concentration from about 144 to about 176 ppm for a first period of time, followed by a gas mixture containing no nitric oxide for a second period of time, wherein the administration is repeated for a time sufficient to: a) reduce the level of at least one inflammatory biomarker in the human subject when compared to the level of the inflammatory biomarker prior to the administration; b) reduce the microbial density by 1 to 2 log units as measured by colony forming units in the human subject when compared to the microbial density prior to the administration; or c) a combination thereof.
Owner:ADVANCED INHILATION THERAPIES AIT LTD
Carbon monoxide as a biomarker and therapeutic agent
InactiveUS7678390B2Reduce concentrationInhibiting and alleviating effectBiocideInorganic active ingredientsRESPIRATORY DISTRESS SYNDROME ADULTInterstitial lung disease
The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent of heart, lung, liver, spleen, brain, skin and kidney diseases and other conditions and disease states including, for example, asthma, emphysema, bronchitis, adult respiratory distress syndrome, sepsis, cystic fibrosis, pneumonia, interstitial lung diseases, idiopathic pulmonary diseases, other lung diseases including primary pulmonary hypertension, secondary pulmonary hypertension, cancers, including lung, larynx and throat cancer, arthritis, wound healing, Parkinson's disease, Alzheimer's disease, peripheral vascular disease and pulmonary vascular thrombotic diseases such as pulmonary embolism. CO may be used to provide anti-inflammatory relief in patients suffering from oxidative stress and other conditions especially including sepsis and septic shock. In addition, carbon monoxide may be used as a biomarker or therapeutic agent for reducing respiratory distress in lung transplant patients and to reduce or inhibit oxidative stress and inflammation in transplant patients.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (RSV) infection
Medicinal use The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of respiratory syncitial virus (RSV) infection in particular viral exacerbation of a respiratory disorder such as bronchitis, asthma, COPD and / or cystic fibrosis, methods of treating or preventing RSV infection employing said compounds or pharmaceutical composition comprising the same.
Owner:RESPIVERT
Compositions and methods for treating asthma and other lung disorders
InactiveUS20120114702A1Sufficient amountAntibacterial agentsPowder deliveryObstructive Pulmonary DiseasesOxygen
Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or symptoms thereof (e g, asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (CaPO) and CaPO-associated conditions (e g, bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, in-fluenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) comprising administering a therapeutic composition comprising at least one electrokinetically altered fluid comprising an ionic aqueous solution of charge-stabilized oxygen containing nanostructures as disclosed herein, or comprising administering a nonelectrokinetic superoxygenated aqueous solution The methods preferably comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e g, membrane receptors, (e g, G protein-coupled receptors, and intercellular junctions)) Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent (e g, albuterol, etc).
Owner:REVALESIO CORP
Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
InactiveUS20050065141A1Satisfies needBiocideOrganic active ingredientsPulmonary infectionIndoschulzia
The present invention provides carbapenems to treat or prevent pulmonary infections, particularly in patients with cystic fibrosis, pneumonia, ventilator associated pneumonia, bronchitis or bronchiectstasis, pharmaceutical compositions of these carbapenems and methods of administering these carbapenems to treat or prevent pulmonary infections.
Owner:PENINSULA PHARMA
Attenuated vaccine strain for avian infectious bronchitis virus and application thereof
InactiveCN102851257AImprove securityInactivation/attenuationMicroorganism based processesInfectious bronchitisFowl
The method relates to an attenuated vaccine strain for avian infectious bronchitis virus and application thereof. According to the invention, avian infectious bronchitis virus (IBV) is attenuated, so as to successfully obtain an IBV attenuated strain CCTCC.V201232 and a derivative virus strain thereof. The attenuated strain and derivative virus strain provided by the invention can be used in preparation of a vaccine composition for prevention of infectious bronchitis. Experiments show that the attenuated strain and vaccine composition provided by the invention can be inoculated to immature birds, so as to effectively activate immune system in the birds and well prevent avian infectious bronchitis.
Owner:SHANGHAI QISHENG BIOTECH CO LTD
Health care beverage of sugar cane juice
InactiveCN1957771APrevent nephritisPrevent kidney failureFood preparationPlant ingredientsMedicinal herbsGLYCYRRHIZA EXTRACT
A health-care sugar cane juice beverage for preventing nephritis, renal failure and uremia, and treating cough and bronchitis is prepared from sugar can juice and 16 Chinese-medicinal materials including wolfberry fruit, honeysuckle flower, liquorice root, scutellaria root, etc.
Owner:曹喜元
Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
InactiveCN101636386AHas CRTH2 binding activityOrganic active ingredientsSenses disorderAllergic dermatitisDisease
The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.
Owner:ASTELLAS PHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com